Products
Carotuximab Biosimilar Monoclonal Antibody (CD105) for Research
Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-095-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody |
| INN Name | Carotuximab |
| Target | ENG |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration |
| Development Tech | na |
About target - ENG
1. Protein Endoglin
2. Gene ENG
3. Organism Homo sapiens (Human)
Function
Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis (PubMed:21737454, PubMed:23300529).
Required for normal structure and integrity of adult vasculature (PubMed:7894484).
Regulates the migration of vascular endothelial cells (PubMed:17540773).
Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity).
May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis (By similarity).
May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors (PubMed:1692830).
Acts as TGF-beta coreceptor and is involved in the TGF-beta/BMP signaling cascade that ultimately leads to the activation of SMAD transcription factors (PubMed:8370410, PubMed:21737454, PubMed:22347366, PubMed:23300529).
Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGFB1 signaling through SMAD3 (PubMed:21737454, PubMed:22347366, PubMed:23300529).
